New monthly shot could simplify anemia treatment for kidney patients
NCT ID NCT00560404
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether a once-monthly injection of Mircera works as well as the standard epoetin alfa treatment for managing anemia in people on dialysis. About 233 adults with chronic kidney disease-related anemia participated. The goal was to see if Mircera could keep hemoglobin levels stable within a healthy range, offering a more convenient dosing schedule.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mircera (methoxy polyethylene glycol-epoetin beta)
What this could lead to
If successful, this could offer dialysis patients a more convenient once-monthly injection option to manage anemia, reducing the need for more frequent dosing.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all patients. The main risk is that Mircera may not control hemoglobin as effectively as standard treatment, potentially leading to anemia-related complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Belo Horizonte, 30150-320, Brazil
-
Study site
Brasília, 70390-108, Brazil
-
Study site
Campinas, 13086-970, Brazil
-
Study site
Campo Grande, 79002-073, Brazil
-
Study site
Cariacica, 29152-230, Brazil
-
Study site
Curitiba, 80050-350, Brazil
-
Study site
Curitiba, 80440-020, Brazil
-
Study site
Fortaleza, 60430160, Brazil
-
Study site
Jaboatão dos Guararapes, 54400-170, Brazil
-
Study site
Joinville, 89227-680, Brazil
-
Study site
Juiz de Fora, 36036900, Brazil
-
Study site
Londrina, 86015-000, Brazil
-
Study site
Natal, 59020-110, Brazil
-
Study site
Porto Alegre, 90035-903, Brazil
-
Study site
Porto Alegre, 90610000, Brazil
-
Study site
Ribeirão Preto, 14025-170, Brazil
-
Study site
Rio de Janeiro, Brazil
-
Study site
Salvador, 40110-060, Brazil
-
Study site
São José do Rio Preto, 15090-000, Brazil
-
Study site
São Luís, 65020-305, Brazil
-
Study site
São Paulo, 01246-903, Brazil
-
Study site
São Paulo, 01323-900, Brazil
-
Study site
São Paulo, 01532-001, Brazil
-
Study site
São Paulo, 03065-000, Brazil
-
Study site
São Paulo, O4023, Brazil
-
Study site
Sorocaba, 18030-210, Brazil